Corbus Pharmaceuticals Holdings Inc. announced the appointment of Rachelle Jacques as the new Chair of its Board of Directors, effective May 15, 2025. Ms. Jacques succeeds Alan Holmer, who will continue to serve as a member of the Board. This leadership change is a strategic move as Corbus advances its diverse pipeline towards key clinical milestones.
Ms. Jacques brings over 25 years of extensive leadership experience across CEO, commercial, financial, and operational roles within the biopharmaceutical industry. Her track record includes successfully advancing and launching transformative therapies. She previously served as CEO of Akari Therapeutics Plc and Enzyvant Therapeutics, where she led the U.S. Food and Drug Administration approval of RETHYMIC.
Her deep and broad corporate experience in both large pharmaceutical companies and biotech firms is expected to provide valuable guidance as Corbus navigates its next chapter. The company anticipates clinical readouts from all three of its pipeline drugs, CRB-701, CRB-601, and CRB-913, in the second half of 2025. This appointment strengthens the company's governance and strategic oversight during a pivotal period.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.